Welcome to our dedicated page for Currenc Group news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group stock.
Currenc Group Inc. (Nasdaq: CURR) regularly issues news updates that describe its activities as a fintech company focused on artificial intelligence (AI) solutions for financial institutions and digital remittance services. Its press releases cover both operational developments and corporate transactions, providing context for investors and other readers who follow CURR news.
Readers of this news feed can expect coverage of financial results, including quarterly and half-year reports that discuss Total Processing Value (TPV) through Tranglo, remittance revenues, airtime revenues, gross margin and EBITDA. These releases often include management commentary on remittance performance, shifts away from lower-margin airtime transfers and the expansion of AI initiatives.
Currenc’s news also highlights strategic and capital-structure actions. Examples in the supplied disclosures include a proposed reverse merger with Animoca Brands Corporation Limited, a definitive agreement to divest its 60% controlling interest in Tranglo to New Margin Holding Limited, convertible note financings with warrants, and a shares-for-debt transaction in which related party loans were converted into equity. Such announcements describe how the company intends to reshape its business mix, reduce debt and support AI, Web3 and digital assets initiatives.
Additional news items address governance and leadership, such as CEO transitions and amendments to executive employment agreements, as well as steps the company has taken to monitor potential naked short selling in its stock. Together, these categories of news provide insight into how Currenc presents its operational performance, strategic direction and shareholder-related actions over time.
Investors and observers who follow CURR news can use this stream of press releases to track updates on remittance operations, AI product development, proposed corporate combinations and financing arrangements as described directly by the company in its public communications.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has received FDA approval for its Investigational New Drug (IND) application for CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This product is being developed using the CUREfilm™ technology, which offers a convenient alternative to traditional pills. The global ED drug market is projected to reach USD $6.6 billion by 2025, presenting significant market potential for CUREfilm Blue™. This milestone validates CURE's technology and opens opportunities for further clinical trials.
CURE Pharmaceutical Holdings (OTCQB: CURR) will present at the LD Micro Main Event Conference on December 15, 2020, at 11:00 AM PT. A video webcast for investors is scheduled for December 17, 2020, at 4:00 PM ET, featuring key executives discussing the company's strategic positioning. Shareholders can submit questions via email by December 15 at 6 PM ET for potential answers during the webcast. Archived versions will also be available post-event. The company focuses on innovative pharmaceutical technology and wellness products, with international partnerships for manufacturing.